Dashboard
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Net Sales has grown by an annual rate of 11.46% and Operating profit at 5.18% over the last 5 years
3
Negative results in Jun 25
4
Risky - Negative EBITDA
Stock DNA
Pharmaceuticals & Biotechnology
JPY 6,174 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.89
-69.81%
3.30
Revenue and Profits:
Net Sales:
17 Million
(Quarterly Results - Jun 2025)
Net Profit:
-200 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
22.11%
0%
22.11%
6 Months
90.16%
0%
90.16%
1 Year
34.88%
0%
34.88%
2 Years
-22.15%
0%
-22.15%
3 Years
13.73%
0%
13.73%
4 Years
-16.55%
0%
-16.55%
5 Years
-46.79%
0%
-46.79%
Medrx Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.46%
EBIT Growth (5y)
5.18%
EBIT to Interest (avg)
-1,187.04
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.90
Sales to Capital Employed (avg)
0.06
Tax Ratio
0.50%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.68
EV to EBIT
-1.30
EV to EBITDA
-1.34
EV to Capital Employed
7.64
EV to Sales
5.17
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-589.40%
ROE (Latest)
-61.29%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
16.60
2.20
654.55%
Operating Profit (PBDIT) excl Other Income
-188.70
-409.80
53.95%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-200.40
-429.10
53.30%
Operating Profit Margin (Excl OI)
-11,454.70%
-190,985.00%
17,953.03%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 654.55% vs -18.52% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 53.30% vs 11.82% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
257.90
29.50
774.24%
Operating Profit (PBDIT) excl Other Income
-754.60
-888.00
15.02%
Interest
0.00
0.00
Exceptional Items
-47.70
0.60
-8,050.00%
Consolidate Net Profit
-806.80
-932.90
13.52%
Operating Profit Margin (Excl OI)
-3,074.80%
-31,609.90%
2,853.51%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 774.24% vs -50.42% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 13.52% vs 16.05% in Dec 2023
About Medrx Co., Ltd. 
Medrx Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






